Supernus Pharmaceuticals, Inc. SUPN
42.66
(0.63)
(1.46%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow SUPN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(1.86%) | (3.68%) | (2.75%) | (10.49%) | |
| (1.38%) | (2.73%) | (2.04%) | (7.82%) | ||
ROIC |
(3.00%) | (5.17%) | (5.45%) | (12.37%) | |
Return on Tangible Assets |
(6.98%) | (12.18%) | (7.89%) | (28.44%) | |
Average Days of Receivables |
91.72 | 95.34 | 85.60 | 93.03 | |
Free Cash Flow per Share |
1.25 | 0.81 | 1.44 | 0.32 | |
Free Cash Flow |
70.75 | 45.99 | 83.26 | 18.33 | |
Capital Expenditures |
(1.12) | (1.34) | — | (1.58) | |
Piotroski F-Score |
2.00 | 4.00 | 4.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
5.40% | 3.45% | 5.70% | 1.42% | |
Accounts Receivable Turnover |
4.30 | 4.36 | 4.74 | 4.71 | |
Accounts Payable Turnover |
0.84 | 0.81 | 0.92 | 1.06 | |
Inventory Turnover |
1.08 | 1.09 | 1.20 | 1.55 | |
Average Days of Payables |
510.52 | 527.71 | 449.62 | 399.74 | |
Days of Inventory on Hand |
373.21 | 403.30 | 386.64 | 309.32 | |
Tax Rate |
(0.08) | (0.21) | (0.41) | (0.11) | |
Research and Development Expense of Revenue |
15.71% | 14.78% | 15.29% | 15.18% | |
Selling, General and Administrative Expense of Revenue |
64.94% | 67.54% | 67.04% | 67.54% | |
Share Based Compensation of Revenue |
4.55% | 4.60% | 4.31% | 4.17% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(3.76) | (1.23) | (2.87) | (0.18) | |
Depreciation/Fixed assets |
7.78 | 8.55 | 9.63 | 9.88 | |
Capex/Depreciation |
(0.01) | (0.01) | 0.00 | (0.02) | |
Revenue per Share |
12.05 | 12.74 | 13.48 | 14.30 | |
Operating CF per Share |
1.27 | 0.84 | 1.44 | 0.34 | |
Capex per Share |
(0.02) | (0.02) | 0.00 | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(2.80%) | (5.36%) | (3.74%) | (13.23%) |
Columns are period end dates